Akero Therapeutics, Inc. (AKRO) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in South San Francisco, CA, United States. Der aktuelle CEO ist Andrew Cheng.
AKRO hat IPO-Datum 2019-06-20, 69 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $4.5B.
Akero Therapeutics, Inc. is a cardio-metabolic company focused on developing treatments for nonalcoholic steatohepatitis (NASH) and related metabolic disorders. The company's lead product candidate is efruxifermin (EFX), a fibroblast growth factor 21 analog designed to restore metabolic balance by protecting against cellular stress and regulating the metabolism of lipids, carbohydrates, and proteins throughout the body. Akero is advancing efruxifermin through clinical development, including the Phase 2a BALANCED study evaluating its efficacy in biopsy-confirmed NASH patients. Headquartered in South San Francisco, California, the company was founded in 2017 and rebranded from its former name, Pippin Pharmaceuticals, Inc., in May 2018.
